Get the Stockscreener App
6.35
4.51%
-0.30
After Hours:
6.39
0.04
+0.63%
Nextcure Inc stock is traded at $6.35, with a volume of 9,933.
It is down -4.51% in the last 24 hours and up +17.69% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$6.65
Open:
$6.58
24h Volume:
9,933
Relative Volume:
0.09
Market Cap:
$16.99M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-3.0383
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
+5.83%
1M Performance:
+17.69%
6M Performance:
+2,082%
1Y Performance:
+347.18%
1-Day Range:
$6.2429
$6.71
1-Week Range:
$5.8176
$6.99
52-Week Range:
$0.224
$6.99
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
6.35 | 17.80M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
Predicting NextCure Inc. trend using moving averagesEarnings Performance Report & Precise Swing Trade Entry Alerts - newser.com
Why analysts remain bullish on NextCure Inc. stockJuly 2025 Summary & Risk Managed Investment Signals - newser.com
What drives NextCure Inc stock priceHigh Frequency Trading Trends & High Profit Trading Signals - earlytimes.in
Quantitative breakdown of NextCure Inc. recent moveGold Moves & Fast Exit Strategy with Risk Control - newser.com
Will breakout in NextCure Inc. lead to full recoveryJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
How to use Fibonacci retracement on NextCure Inc.Trade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Using Ichimoku Cloud for NextCure Inc. technicalsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
NextCure (NASDAQ:NXTC) Shares Up 1.2% – What’s Next? - Defense World
Using portfolio simulators with NextCure Inc. included2025 Trade Ideas & Verified Short-Term Plans - newser.com
Can momentum traders help lift NextCure Inc.Weekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
What high frequency data says about NextCure Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Will NextCure Inc. stock outperform growth indexesJuly 2025 Decliners & Breakout Confirmation Alerts - newser.com
Why NextCure Inc. is moving todayTrade Entry Report & Reliable Price Breakout Signals - newser.com
What machine learning models say about NextCure Inc.July 2025 Analyst Calls & Daily Technical Stock Forecast Reports - newser.com
Is NextCure Inc. stock a buy for dividend growthJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Is it too late to sell NextCure Inc.July 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
Real time social sentiment graph for NextCure Inc.Weekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com
Volatility clustering patterns for NextCure Inc.July 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - newser.com
Will a bounce in NextCure Inc. offer an exitJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Is NextCure Inc a good long term investmentCovered Call Writing & Collaborate and Win Together - earlytimes.in
NextCure Inc. stock chart pattern explainedTrade Risk Summary & Step-by-Step Swing Trade Plans - newser.com
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):